Recall rebound boosts J&J quarterly results

Johnson & Johnson ended the first quarter with $17.5 billion in sales, an 8.5% increase over the same period last year.

US sales were $8 billion, up just over 11% compared to the same period last year, and international sales were $9.5 billion, up just over 6%. Consumer products – which includes baby care, oral care, and OTC medications, among other categories – saw sales rise 2% over the same period last year, to $3.7 billion, up from $3.6 billion. Part of this growth comes from getting products back on shelves after a series of recalls.

Pharmaceutical sales were up around 15% in the US and 6% internationally. Notable growth spots included biologic Stelara, with sales rising 57% overall, compared to the same period last year, and 75% in the US, to $226 million, and to $120 million internationally. Sales of schizophrenia medication Invega rose 64% in the US, to $164 million for the quarter, and 98% internationally, to $120 million. Sales of prostate cancer drug Zytiga sales rose 72% overall, to $344 million, with  $161 million in US sales and $183 million internationally.
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.